News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Cybin Inc. (NYSE: CYBN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder [Yahoo! Finance]

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $96.00 to $86.00. They now have a "buy" rating on the stock.

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

6/26/2024

07:31 am

cybn

4.4%

MISS

Form 6-K CYBIN INC. For: Nov 18

Form SC 13G/A CYBIN INC. Filed by: Point72 Asset Management, L.P.

Form SC 13G/A CYBIN INC. Filed by: Logos Global Management LP

Form 6-K CYBIN INC. For: Nov 14

Form 6-K CYBIN INC. For: Nov 13

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}